hydrocodone has been researched along with Neuralgia--Postherpetic* in 1 studies
1 other study(ies) available for hydrocodone and Neuralgia--Postherpetic
Article | Year |
---|---|
An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population.
This study updated our knowledge of UK primary care neuropathic pain incidence rates and prescribing practices.. Patients with a first diagnosis of post-herpetic neuralgia (PHN), painful diabetic neuropathy (PDN) or phantom limb pain (PLP) were identified from the General Practice Research Database (2006 - 2010) and incidence rates were calculated. Prescription records were searched for pain treatments from diagnosis of these conditions and the duration and daily dose estimated for first-line and subsequent treatment regimens. Recording of neuropathic back and post-operative pain was investigated.. The study included 5,920 patients with PHN, 5,340 with PDN, and 185 with PLP. The incidence per 10,000 person-years was 3.4 (95% CI 3.4, 3.5) for PHN; and 0.11 (95% CI 0.09, 0.12) for PLP. Validation of the PDN case definition suggested that was not sensitive. Incident PHN increased over the study period. The most common first-line treatments were amitriptyline or gabapentin in the PDN and PLP cohorts, and amitriptyline or co-codamol (codeine-paracetamol) in PHN. Paracetamol, co-dydramol (paracetamol-dihydrocodeine) and capsaicin were also often prescribed in one or more condition. Most first-line treatments comprised only one therapeutic class. Use of antiepileptics licensed for neuropathic pain treatment had increased since 2002-2005. Amitriptyline was the only antidepressant prescribed commonly as a first-line treatment.. The UK incidence of diagnosed PHN has increased with the incidence of back-pain and post-operative pain unclear. While use of licensed antiepileptics increased, prescribing of therapy with little evidence of efficacy in neuropathic pain is still common and consequently treatment was often not in-line with current guidance. Topics: Acetaminophen; Adolescent; Adult; Aged; Amines; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, Opioid; Anticonvulsants; Capsaicin; Child; Child, Preschool; Codeine; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Drug Combinations; Drug Prescriptions; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydrocodone; Incidence; Infant; Male; Middle Aged; Neuralgia, Postherpetic; Phantom Limb; Practice Patterns, Physicians'; Primary Health Care; Sensory System Agents; United Kingdom; Young Adult | 2013 |